Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy targets rare abdominal cancer

NCT ID NCT03875144

Disease control Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a special chemotherapy spray (PIPAC) directly into the abdomen to standard IV chemo can help people with a rare cancer of the belly lining (peritoneal mesothelioma) live longer. About 66 adults who have not had prior treatment will be randomly assigned to receive either standard chemo alone or standard chemo plus PIPAC. The trial is currently suspended.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2020

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. PS (or WHO) \<2 3. Histologically-confirmed diagnosis of peritoneal malignant mesothelioma 4. No previous line of treatment (both medical and surgical oncologic treatments) for this disease 5. Peritoneal Carcinomatosis Index (PCI)\>27 or at least 4 on the small bowel with serosal involvement contraindicating the cytoreductive surgery because of the impossibility to preserve a length \>=1.5 m of uninvolved small bowel 6. Written and dated informed consent 7. Affiliated to the French national social security system Exclusion Criteria: 1. WHO performance status ≥ 2 2. Any contraindication to chemotherapy and/or radiotherapy 3. Any contraindication to repeated laparoscopy 4. Symptomatic cardiac or coronary insufficiency 5. Severe renal insufficiency 6. Progressive active infection or any other severe medical condition 7. Intestinal occlusion non responsive to medical treatment 8. Other cancer treated within the last 2 years except in situ cervical carcinoma or basocellular/spinocellular carcinoma 9. Pregnant or breast-feeding woman 10. Previously operated patients where laparoscopy is not feasible 11. Persons deprived of liberty or under guardianship or incapable of giving consent 12. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol or follow-up schedule

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant peritoneal mesothelioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant peritoneal mesothelioma peritoneal carcinomatosis peritoneal mesothelioma peritoneal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peritoneal carcinomatosis Peritoneal mesothelioma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institut réginal du Cancer de Montpellier

    Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.